Editorial

Abstract

I am very pleased to announce that the Editorial Team for the Journal of Pharmaceutical Sciences (JPharmSci®) plans to generate a Special Issue entitled “Two Decades of Publishing Excellence in Pharmaceutical Biotechnology” to highlight the journal's contributions to the clinical success of biotechnology‐based drugs (e.g., peptides, proteins, antibodies, vaccines, DNA, and RNA), which have now been used in the prevention and treatment of human and animal diseases for more than 20 yearsIn January 1994, the then Editor of JPharmSci®, Professor William I. Higuchi (University of Utah), had the vision and foresight to recruit C. Russell Middaugh to join JPharmSci®'s Editorial Team as the Associate Editor having responsibilities for building the journal's presence in a new, rapidly emerging area of the pharmaceutical sciences (i.e., pharmaceutical biotechnology) that focused on the characterization, stabilization, formulation and delivery of drugs, and drug candidates forthcoming from so‐called “biotechnology companies”. At the time, Dr. Middaugh was a Senior Scientist in Pharmaceutical Research and Vaccine Development at Merck and Company. In 1997, Dr. Middaugh assumed the position of the Takeru and Aya Higuchi Distinguished Professor in Pharmaceutical Chemistry at The University of Kansas, a position he still holds today.Thanks to Professor Higuchi's vision and foresight and Professor Middaugh's dedication and commitment to the journal, JPharmSci® will celebrate in January 2014 “two decades of publishing excellence” in the area of pharmaceutical biotechnology.Therefore, JPharmSci®'s Editorial Team, as well as the journal's sponsor (American Pharmacists Association) and publisher (Wiley Periodicals, Inc.), felt that this event should be recognized through the generation of a Special Issue entitled “Two Decades of Publishing Excellence in Pharmaceutical Biotechnology.”This Special Issue will include original scientific papers (Research Articles, Notes, and Rapid Communications), Perspectives, Reviews, Minireviews, Lessons Learned, and Commentaries that highlight the scientific category of “Pharmaceutical Biotechnology” as defined in JPharmSci®'s Authors’ Guidelines and reproduced below: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1520-6017/homepage/ForAuthors.html“Manuscripts in this scientific category should include descriptions of quantitative and mechanistic research in pharmaceutics, drug delivery and pharmaceutical technology that are normally conducted during the preclinical and clinical drug development of biotechnology‐based drug candidates and drugs (e.g. peptides, proteins, antibodies, vaccines, DNA, RNA). Research results of particular interest to the readers of JPharmSci® would include those that afford valuable, new information about how a molecule's in vitro and in vivo behavior is influenced by its molecular and physico‐chemical properties, traditional formulations and novel drug delivery systems used in preclinical and clinical studies and the manufacturing processes that give rise to the final drug product. This scientific category would also encompass manuscripts that describe: (i) new and novel analytical methodologies that would facilitate and/or more accurately and completely characterize the physico‐chemical and biological properties of biotechnology‐based drug candidates and drugs; and (ii) new and novel formulations strategies and drug delivery systems, including those built on bio‐and nanotechnologies, that would enhance the delivery of these types of molecules to their pharmacological targets in animals and humans.”I am pleased to announce here that John Carpenter (University of Colorado‐Denver), Susan Hershenson (Gates Foundation), Rodney Ho (University of Washington), Susumu Uchiyama (Osaka University), David Volkin (University of Kansas), and Gerhard Winter (Ludwig Maximilians Universitat) have agreed to serve as the Guest Editors for this Special Issue of JPharmSci®.These Guest Editors would welcome proposals for original scientific papers (Research Articles, Notes, and Rapid Communications), Perspectives, Reviews, Minireviews, Lessons Learned, and Commentaries in the area of “pharmaceutical biotechnology” as defined above.If you are interested in contributing to this Special Issue, please contact Prof. John Carpenter at john.carpenter@ucdenver.edu or Prof. David Volkin at volkin@ku.edu for more details.Finally, we anticipate that the Special Issue entitled “Two Decades of Publishing Excellence in Pharmaceutical Biotechnology” will appear as the February 2015 issue of JPharmSci®. I am very pleased to announce that the Editorial Team for the Journal of Pharmaceutical Sciences (JPharmSci®) plans to generate a Special Issue entitled “Two Decades of Publishing Excellence in Pharmaceutical Biotechnology” to highlight the journal's contributions to the clinical success of biotechnology‐based drugs (e.g., peptides, proteins, antibodies, vaccines, DNA, and RNA), which have now been used in the prevention and treatment of human and animal diseases for more than 20 years In January 1994, the then Editor of JPharmSci®, Professor William I. Higuchi (University of Utah), had the vision and foresight to recruit C. Russell Middaugh to join JPharmSci®'s Editorial Team as the Associate Editor having responsibilities for building the journal's presence in a new, rapidly emerging area of the pharmaceutical sciences (i.e., pharmaceutical biotechnology) that focused on the characterization, stabilization, formulation and delivery of drugs, and drug candidates forthcoming from so‐called “biotechnology companies”. At the time, Dr. Middaugh was a Senior Scientist in Pharmaceutical Research and Vaccine Development at Merck and Company. In 1997, Dr. Middaugh assumed the position of the Takeru and Aya Higuchi Distinguished Professor in Pharmaceutical Chemistry at The University of Kansas, a position he still holds today. Thanks to Professor Higuchi's vision and foresight and Professor Middaugh's dedication and commitment to the journal, JPharmSci® will celebrate in January 2014 “two decades of publishing excellence” in the area of pharmaceutical biotechnology. Therefore, JPharmSci®'s Editorial Team, as well as the journal's sponsor (American Pharmacists Association) and publisher (Wiley Periodicals, Inc.), felt that this event should be recognized through the generation of a Special Issue entitled “Two Decades of Publishing Excellence in Pharmaceutical Biotechnology.” This Special Issue will include original scientific papers (Research Articles, Notes, and Rapid Communications), Perspectives, Reviews, Minireviews, Lessons Learned, and Commentaries that highlight the scientific category of “Pharmaceutical Biotechnology” as defined in JPharmSci®'s Authors’ Guidelines and reproduced below: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1520-6017/homepage/ForAuthors.html “Manuscripts in this scientific category should include descriptions of quantitative and mechanistic research in pharmaceutics, drug delivery and pharmaceutical technology that are normally conducted during the preclinical and clinical drug development of biotechnology‐based drug candidates and drugs (e.g. peptides, proteins, antibodies, vaccines, DNA, RNA). Research results of particular interest to the readers of JPharmSci® would include those that afford valuable, new information about how a molecule's in vitro and in vivo behavior is influenced by its molecular and physico‐chemical properties, traditional formulations and novel drug delivery systems used in preclinical and clinical studies and the manufacturing processes that give rise to the final drug product. This scientific category would also encompass manuscripts that describe: (i) new and novel analytical methodologies that would facilitate and/or more accurately and completely characterize the physico‐chemical and biological properties of biotechnology‐based drug candidates and drugs; and (ii) new and novel formulations strategies and drug delivery systems, including those built on bio‐and nanotechnologies, that would enhance the delivery of these types of molecules to their pharmacological targets in animals and humans.” I am pleased to announce here that John Carpenter (University of Colorado‐Denver), Susan Hershenson (Gates Foundation), Rodney Ho (University of Washington), Susumu Uchiyama (Osaka University), David Volkin (University of Kansas), and Gerhard Winter (Ludwig Maximilians Universitat) have agreed to serve as the Guest Editors for this Special Issue of JPharmSci®. These Guest Editors would welcome proposals for original scientific papers (Research Articles, Notes, and Rapid Communications), Perspectives, Reviews, Minireviews, Lessons Learned, and Commentaries in the area of “pharmaceutical biotechnology” as defined above. If you are interested in contributing to this Special Issue, please contact Prof. John Carpenter at john.carpenter@ucdenver.edu or Prof. David Volkin at volkin@ku.edu for more details. Finally, we anticipate that the Special Issue entitled “Two Decades of Publishing Excellence in Pharmaceutical Biotechnology” will appear as the February 2015 issue of JPharmSci®.